SONEAS Acquisition

SONEAS Acquisition

slide 1

Vivimed Labs Spain S.L, the parent of UQUIFA S.A, has signed definitive agreements to facilitate the acquisition of SONEAS, a Budapest (Hungary) headquartered CDMO company, focussed on the Innovator Pharmaceutical and Fine Chemical sectors. The business has been acquired from Lochlomond and Euroventures which are both based out of Hungary. SONEAS has for the year 2017, reported revenues of €12.2mn.

The acquisition broadens UQUIFA´s market offering in the CDMO space by enhancing its ability to now undertake preclinical, phase I, II and III NCE project development. These projects can then also potentially feed into UQUIFA´s existing cGMP inspected and approved manufacturing facilities in Spain and Mexico, creating a high-value project pipeline.

About SONEAS

SONEAS, established in 1996, with a team strength of 144 people, is a Budapest, Hungary headquartered firm with business verticals focused on R+D and CMO, targeted at the Innovator Pharma and Fine Chemical sectors.In R+D, it is a professional chemical service provider with research and analytical labs across two operating sites in Budapest. It also has an 8,000 sq mtr facility which houses process R+D, kilo lab and a cGMP approved pilot plant facility which was commissioned in 2002. In CMO, it is operating on 65,000 m2 site and capable of providing starting materials, intermediates for pharma and non-pharma applications as well as other fine chemical products on a commercial scale. SONEAS existing customer base includes names like Chinoin, Ogeda, Eisai, Leo Pharma among others.

For further information on SONEAS, visit www.soneas.com